Skip to content

Study · Animal study (in vivo) · mouse · 2001

7 results

Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.

McCutcheon IE, Flyvbjerg A, Hill H, Li J, Bennett WF, Scarlett JA, Friend KE

Journal of neurosurgery1 Mar 2001Cited by 87 (Europe PMC)

PMID11235955 (opens in a new tab)DOI10.3171/jns.2001.94.3.0487 (opens in a new tab)PepBankPUB-11235955
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with human meningioma xenografts, pegvisomant reduced tumor volume to 198.3 +/- 18.9 versus 350.1 +/- 23.5 mm3 with vehicle (p < 0.001).

    In plain wordsIn mice with human meningioma xenografts, pegvisomant reduced tumor volume versus vehicle.

    Peptide
    Pegvisomant
    Outcome
    DecreaseTumor volume
    Study

    mousen = 30

    Human meningioma xenografts in athymic mice
    Comparator
    Vehicle
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    After 8 weeks of treatment, the mean volume of tumors in the pegvisomant group was 198.3 +/- 18.9 mm3 compared with 350.1 +/- 23.5 mm3 for the vehicle group (p < 0.001).
    2 context sentences
    Summary · context
    Primary cultures from 15 meningioma tumors obtained in humans were xenografted into athymic mice.
    Summary · context
    One animal from each of the 15 pairs was then treated with the GH receptor antagonist pegvisomant and the other with vehicle alone for 8 weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with human meningioma xenografts, serum IGF-I was 257 +/- 9.7 with pegvisomant versus 319 +/- 12.9 microg/L with vehicle (p < 0.02).

    In plain wordsIn mice with human meningioma xenografts, pegvisomant reduced serum IGF-I versus vehicle.

    Peptide
    Pegvisomant
    Outcome
    DecreaseSerum IGF-I
    Study

    mousen = 30

    Human meningioma xenografts in athymic mice
    Comparator
    Vehicle
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The serum IGF-I concentration in the vehicle group was 319 +/- 12.9 microg/L compared with 257 +/- 9.7 in the pegvisomant group (p < 0.02).
    2 context sentences
    Summary · context
    Primary cultures from 15 meningioma tumors obtained in humans were xenografted into athymic mice.
    Summary · context
    One animal from each of the 15 pairs was then treated with the GH receptor antagonist pegvisomant and the other with vehicle alone for 8 weeks.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with human meningioma xenografts, pegvisomant treatment accompanied a small significant decrease in circulating IGFBP-3.

    In plain wordsIn mice with human meningioma xenografts, circulating IGFBP-3 decreased during pegvisomant treatment.

    Peptide
    Pegvisomant
    Outcome
    DecreaseCirculating IGFBP-3
    Study

    mousen = 30

    Human meningioma xenografts in athymic mice
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    A small but significant decrease was observed in circulating IGF binding protein (IGFBP)-3 levels, whereas slight increases occurred with respect to serum IGFBP-1 and IGFBP-4 levels.
    2 context sentences
    Summary · context
    Primary cultures from 15 meningioma tumors obtained in humans were xenografted into athymic mice.
    Summary · context
    One animal from each of the 15 pairs was then treated with the GH receptor antagonist pegvisomant and the other with vehicle alone for 8 weeks.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with human meningioma xenografts, serum IGFBP-1 increased slightly during pegvisomant treatment.

    In plain wordsIn mice with human meningioma xenografts, serum IGFBP-1 increased slightly during pegvisomant treatment.

    Peptide
    Pegvisomant
    Outcome
    IncreaseSerum IGFBP-1
    Study

    mousen = 30

    Human meningioma xenografts in athymic mice
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    A small but significant decrease was observed in circulating IGF binding protein (IGFBP)-3 levels, whereas slight increases occurred with respect to serum IGFBP-1 and IGFBP-4 levels.
    2 context sentences
    Summary · context
    Primary cultures from 15 meningioma tumors obtained in humans were xenografted into athymic mice.
    Summary · context
    One animal from each of the 15 pairs was then treated with the GH receptor antagonist pegvisomant and the other with vehicle alone for 8 weeks.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with human meningioma xenografts, serum IGFBP-4 increased slightly during pegvisomant treatment.

    In plain wordsIn mice with human meningioma xenografts, serum IGFBP-4 increased slightly during pegvisomant treatment.

    Peptide
    Pegvisomant
    Outcome
    IncreaseSerum IGFBP-4
    Study

    mousen = 30

    Human meningioma xenografts in athymic mice
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    A small but significant decrease was observed in circulating IGF binding protein (IGFBP)-3 levels, whereas slight increases occurred with respect to serum IGFBP-1 and IGFBP-4 levels.
    2 context sentences
    Summary · context
    Primary cultures from 15 meningioma tumors obtained in humans were xenografted into athymic mice.
    Summary · context
    One animal from each of the 15 pairs was then treated with the GH receptor antagonist pegvisomant and the other with vehicle alone for 8 weeks.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice with human meningioma xenografts, tumor weight was 0.057 +/- 0.01 g with pegvisomant versus 0.092 +/- 0.01 g with placebo (p < 0.02).

    In plain wordsIn mice with human meningioma xenografts, pegvisomant reduced tumor weight versus placebo.

    Peptide
    Pegvisomant
    Outcome
    DecreaseTumor weight
    Study

    mousen = 30

    Human meningioma xenografts in athymic mice
    Comparator
    Placebo
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In the placebo group the tumor weight was 0.092 +/- 0.01 g compared with 0.057 +/- 0.01 g in the pegvisomant group (p < 0.02).
    2 context sentences
    Summary · context
    Primary cultures from 15 meningioma tumors obtained in humans were xenografted into athymic mice.
    Summary · context
    One animal from each of the 15 pairs was then treated with the GH receptor antagonist pegvisomant and the other with vehicle alone for 8 weeks.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In mice with human meningioma xenografts, tumor IGF-I ranged from 0-38.2 ng/g tissue and did not differ significantly between pegvisomant and vehicle.

    In plain wordsIn mice with human meningioma xenografts, tumor IGF-I did not differ significantly between pegvisomant and vehicle.

    Peptide
    Pegvisomant
    Outcome
    No significant changeTumor IGF-I
    Study

    mousen = 30

    Human meningioma xenografts in athymic mice
    Comparator
    Vehicle
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The IGF-I levels were highly variable (0-38.2 ng/g tissue) and did not differ significantly between treatment groups.
    2 context sentences
    Summary · context
    Primary cultures from 15 meningioma tumors obtained in humans were xenografted into athymic mice.
    Summary · context
    One animal from each of the 15 pairs was then treated with the GH receptor antagonist pegvisomant and the other with vehicle alone for 8 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.